Article
22 Oct 2026
FDA Submits Interim Peptide Compounding Policy For White House Review: What Pharmacies Should Know
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
20 Oct 2026
Hospital Mergers And In-House Pharmacies: Licensing, Payor Contracting And Operational Issues That Cannot Wait Until Closing
Article
28 Sep 2026
FDA Warning Letter To Empower Pharmacy And What It Means For 503A Compounding Pharmacies
Article
22 Sep 2026
Buchanan’s PBM & Pharmacy Practice Group Reduce PBM Audit Findings By 100%
Article
20 Aug 2026
Ohio Board of Pharmacy Proposes Expansion of Technology-Enabled Pharmacy Practice
Article
20 Aug 2026
Nevada’s Proposed Pharmacy Staffing Rules Raise A Broader Question: How Should Boards Regulate Workload And Patient Safety?
Article
19 Aug 2026
HRSA Revives The 340B Rebate Pilot: Covered Entities Should Prepare Now For 2027
Article
17 Aug 2026
FDA Extends DSCSA Exemption For Small Pharmacies Through November 27, 2027: What Pharmacies Need To Know
Article
13 Jul 2026
CMS Releases 2027 OPPS Proposed Rule: Key Changes For Hospitals, Health Systems And Healthcare Providers
Article
02 Jul 2026
Texas Telehealth Pharmacy Rule Signals A New Compliance Era: What Every Pharmacy Should Know About The Board’s Proposed Informed Consent Requirements
Article
02 Jul 2026
PBM Terminations: Small Audit Discrepancies Can Still Put Your Pharmacy At Risk
Article
01 Jul 2026
Rhode Island Joins The PBM Oversight Movement: What Senate Bill 3060 Means For Pharmacies, Health Plans And PBM Regulation
Article
01 Jul 2026
Arizona Joins The Growing Movement To Separate PBMs From Pharmacy Ownership
Article
30 Jun 2026
Cassidy’s 340B Reform Discussion Draft Signals A Shift In The Future Of The 340B Program
Article
29 Jun 2026
West Virginia Board Of Pharmacy Adopts New Inspection Rule: What Pharmacies Need To Know Before July 1, 2026
Article
29 Jun 2026
Florida Takes Aim At CVS Caremark: Why The Sunshine State’s Investigation Could Be A Turning Point For PBM Oversight
Article
26 Jun 2026
Maryland Expands Prescriber–Pharmacist Agreements And Opens New Opportunities For Opioid Use Disorder Treatment
Article
26 Jun 2026
Tennessee’s FAIR Rx Act Litigation: Why Independent Pharmacies Should Watch This PBM Fight Closely
Article
24 Jun 2026
Eli Lilly’s 340B Claims-Data Policy: What Covered Entities Need To Know
Article
24 Jun 2026
CMS Signals The Next Major Phase Of PBM Reform: Why Pharmacies And Plan Sponsors Should Pay Attention Now